

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

1. (Currently amended) An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF- $\kappa$ B binding sites, wherein the ~~NF- $\kappa$ B binding sites inhibit~~ oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, and wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

2. (Previously presented) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide sequence has two NF- $\kappa$ B binding sites.

3. (Cancelled)

4. (Currently amended) The isolated tolerogenic dendritic cell of claim 1 further comprising ~~a viral~~ an adenoviral vector encoding CTLA4Ig.

5. (Cancelled)

6. (Cancelled)

7. (Currently amended) A method of producing an isolated tolerogenic dendritic cell comprising (a) propagating an immature isolated dendritic cell from a mammalian donor, (b) incubating the immature isolated dendritic cell with an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site under conditions wherein the immature isolated dendritic cell internalizes the oligodeoxyribonucleotide, wherein the ~~NF- $\kappa$ B binding sites inhibit~~ oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity and (c) culturing the isolated

dendritic cell of (b) to produce the isolated tolerogenic dendritic cell, and wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

8. (Cancelled)

9. (Currently amended) The method of claim 7 further comprising incubating the isolated tolerogenic dendritic cell in the presence of one or more ~~cytokine~~ cytokine(s).

10. (Original) The method of claim 9 wherein the cytokine is GM-CSF.

11. (Previously presented) The method of claim 9 further comprising incubating the isolated tolerogenic dendritic cell in the presence of TGF- $\beta$ .

12. (Currently amended) The method of claim 7 further comprising infecting said isolated tolerogenic dendritic cell with ~~a viral~~ an adenoviral vector encoding CTLA4Ig.

13. (Cancelled)

14. (Cancelled)

15. (Currently amended) A method for enhancing tolerogenicity in a mammalian host comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the immature isolated dendritic cells with an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site under conditions wherein the immature isolated dendritic cells internalize the oligodeoxyribonucleotide, wherein the ~~NF- $\kappa$ B binding sites inhibit~~ oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, (c) culturing the isolated dendritic cells of (b) to produce isolated tolerogenic dendritic cells, and (d) administering said isolated tolerogenic dendritic cells to said host, and

wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.

16. (Cancelled)

17. (Currently amended) The method of claim 15 further comprising incubating said isolated tolerogenic dendritic cells in the presence of one or more ~~cytokine~~ cytokine(s), wherein the cytokine is GM-CSF.

18. (Cancelled)

19. (Previously presented) The method of claim 15 further comprising incubating said isolated tolerogenic dendritic cells in the presence of TGF- $\beta$ .

20. (Currently amended) The method of claim 15 further comprising infecting said isolated tolerogenic dendritic cells with ~~a viral~~ an adenoviral vector encoding CTLA4Ig before administering the cells to said host.

21. (Cancelled)

22. (Cancelled)

23. (Original) The method of claim 15 further comprising administering FK 506 to the host.

24. (Original) The method of claim 15 further comprising administering cyclosporine A to the host.

25. (Original) The method of claim 15 further comprising administering FK 506 and cyclosporine A to the host.

26. (Previously presented) The method of claim 15 or 20 wherein the isolated tolerogenic dendritic cells are administered to the host intravenously.

27. (Original) The method of claim 15 wherein the host is a transplant host.

28. (Original) The method of claim 15 wherein the host has an inflammatory related disease.

29. (Original) The method of claim 28 wherein the host has arthritis.

30. (Currently amended) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site, wherein the ~~NF- $\kappa$ B binding sites inhibit~~ oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, and wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.

31. (Cancelled)

32. (Currently amended) The kit of claim 30 wherein the tolerogenic dendritic cells further comprise ~~a viral~~ an adenoviral vector encoding CTLA4Ig.

33. (Cancelled)

34. (Cancelled)

35-67. (Cancelled)